Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli

• US 8,758,764 B2
• Filed: 02/17/2006
• Issued: 06/24/2014
• Est. Priority Date: 02/18/2005
• Status: Active Grant

• Current Assignee: Glaxosmithkline Vaccines Srl (GlaxoSmithKline PLC), J. Craig Venter Institute
• Original Assignee: J. Craig Venter Institute, Novartis Vaccines And Diagnostics Srl (Novartis Ag)
• Inventors: Masignani, Vega, Moriel, Danilo Gomes, Norais, Nathalie, Fontana, Maria Rita, Pizza, Mariagrazia, Serino, Laura, Tettelin, Herve, Berlanda Scorza, Francesco
• Primary Examiner(s): Baskar, Padma V
• Application Number:
  US11/884,812
• Publication Number:
  US 20080193470A1
• Time in Patent Office: 3,049 Days
• US Class Current: 424/185.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/523 expressing foreign proteins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0258 Escherichia
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/245 Escherichia (G)
• CPC Class Codes: C07K 16/1232 from Escherichia (G)

Abstract

Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.

Claims

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of (a) the sequence which has at least 95% sequence identity to SEQ ID NO:

7052; and

(b) a fragment of SEQ ID NO;

7052, wherein the fragment (i) includes at least 100 consecutive amino acids from SEQ ID NO;

7052;

or (ii) consists of 40 or more consecutive amino acids from SEQ ID NO;

7052.

2. The polypeptide of claim 1, wherein said at least 100 consecutive amino acids or said 40 or more consecutive amino acids comprise at least one B-cell epitope of (a).

3. The substantially purified polypeptide of claim 1, wherein the at least 100 consecutive amino acids or said 40 or more consecutive amino acids consist of (a) said polypeptide without its N-terminal signal polypeptide, or (b) said polypeptide without 1-10 of its N-terminal amino acid residue(s).

4. The substantially purified polypeptide of claim 1 comprising an amino acid sequence which has at least 98% sequence identity to SEQ ID NO 7052.

5. The substantially purified polypeptide of claim 1 comprising an amino acid sequence which has at least 99% sequence identity to SEQ ID NO 7052.

6. The substantially purified polypeptide of claim 1, wherein the fragment includes at least 120 consecutive amino acids from SEQ ID NO 7052.

7. The substantially purified polypeptide of claim 1, wherein the fragment includes at least 140 consecutive amino acids from SEQ ID NO 7052.

8. The substantially purified polypeptide of claim 1, wherein the fragment includes at least 180 consecutive amino acids from SEQ ID NO 7052.

9. The substantially purified polypeptide of claim 1, wherein the fragment consists of 60 or more consecutive amino acids from SEQ ID NO 7052.

10. The substantially purified polypeptide of claim 1, wherein the fragment consists of 80 or more consecutive amino acids from SEQ ID NO 7052.

11. The substantially purified polypeptide of claim 1, wherein the fragment consists of 100 or more consecutive amino acids from SEQ ID NO 7052.

12. An immunogenic composition comprising the polypeptide of claim 1 in admixture with a pharmaceutically acceptable carrier.

13. An immunogenic composition comprising two or more polypeptides of claim 1 in admixture with a pharmaceutically acceptable carrier.

14. The immunogenic composition of claim 13 or claim 12, further comprising a vaccine adjuvant.

15. The immunogenic composition of claim 12, further comprising an adjuvant.

16. The immunogenic composition of claim 15, wherein the adjuvant is an aluminum salt.